Transcription of ANNUAL REPORT 2017 - viforpharma.com
{{id}} {{{paragraph}}}
Example: confidence
ANNUAL REPORT 2017 - viforpharma.com
ANNUAL . REPORT . 2017. ANNUAL REPORT 2017. AT A GLANCE. Guidance raised at half-year, continued good performance in H2. led to strong full-year results Net sales CHF 1, million, up on a constant currency basis EBITDA CHF million, up excluding Veltassa launch costs Cash net of debt of CHF million Transformation into a pure-play pharmaceutical company successfully completed Separation of Galenica Sant via initial public offering (IPO). Etienne Jornod re-elected as Executive Chairman with remuneration exclusively in shares blocked until 2020. Change of name from Galenica Group to Vifor Pharma Group New Executive Committee appointed Operational headquarters transferred from Bern to Zurich Reported net sales growth of Ferinject + for full year 2017. Vifor Fresenius Medical Care Renal Pharma Excellent performance of Velphoro (+ ). Mircera achieves high penetration within the dialysis clinics of Fresenius Medical Care North America (FMCNA) in the US.
2 172 Vifor Pharma Ltd. Annual Report 2017 AT A GLANCE ANNUAL REPORT 2017 Guidance raised at half-year, continued good performance in H2 led to strong full-year results › Net sales CHF 1,342.1 million, up 15.2% on a constant currency basis
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: